In contrast, in the ELIXA trial (once-daily lixisenatide) [29], neither an increase nor a decrease in MACE and the individual component CV events was observed during the follow-up duration (median 2.1 years)
Although research specifically on Retatrutide is limited, data from similar GLP-1 medications suggests nausea may be slightly worse during the luteal phase (days 15-28) when progesterone peaks and GI motility naturally slows
Read the FDAs full warning here: #GLP1 #ClinicalTrials #PatientSafety #AccessEquity #ObesityResearch #DecentralizedTrials To view or add a comment, sign in More Relevant Posts The upheaval of the Health and Human Services workforce and leadership leaves much to be desired in terms of delivery, recently retired FDA Chief Information Officer Vid Desai tells BioSpace, but the regulatory agency is evolving to be more open to much needed change
This means insulin release occurs only when blood glucose levels are elevated, reducing the risk of hypoglycemia compared to some other diabetes medications
My husband learned how from a doctor
Vukojevic et al., 2020), appears as the specific effect of BPC 157 in ischemia/reperfusion (Duzel et al., 2017
